NASHUA, N.H., Oct. 16, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a world medical know-how chief offering modern most cancers detection and remedy options, as we speak introduced that it’s going to host a know-how innovation webinar on the present remedy panorama and unmet medical wants for treating most cancers, on Wednesday, October 21, 2020, at 10am Jap Time.
The decision will characteristic shows by key opinion leaders Santosh Kesari, MD, PhD, John Wayne Most cancers Middle, Janie Grumley, MD, FACS, John Wayne Most cancers Middle and Té Vuong, MD, B.Sc., Fountain Valley Regional Hospital & Medical Middle, who will talk about the present remedy panorama and new modern strategies for treating sufferers with cancers akin to glioblastoma (GBM), breast and rectal.
iCAD’s administration group will present an replace on improvements throughout the detection and remedy companies, together with an summary of iCAD’s breast most cancers risk-assessment resolution, a key ingredient within the transformation from age-based screening to risk-adaptive screening. Additionally highlighted will likely be lately introduced optimistic medical knowledge for Xoft® Mind IORT as a viable remedy choice for GBM. The administration group, together with Drs. Vuong and Santosh will likely be out there to reply questions following the formal shows.
To register for the occasion, please click on here.
Janie Grumley, MD, FACS, is the Director, Complete Breast Program, Director at Margie Petersen Breast Middle and John Wayne Most cancers Institute. She is a surgical breast oncologist who has experience in treating sufferers with breast most cancers and benign breast illnesses. She focuses on novel remedies akin to oncoplastic breast-conserving surgical procedure and intraoperative radiation remedy. Dr. Grumley discovered her path in her third 12 months of residency on the College of Southern California when she met a surgical breast oncologist who was remodeling breast most cancers care with using oncoplastic surgical procedure. She was impressed by the distinction these strategies made in ladies’s lives throughout and after remedy.
Té Vuong, MD, B.Sc., obtained her M.D. from the Université de Montréal and continued her postgraduate coaching in radiation oncology on the College of Toronto and the Institut Gustave Roussy and Institut Curie in Paris, France.
She is a Professor at McGill College within the Division of Oncology, the place she additionally holds the place of Assistant Chair, Radiation Oncology. She was appointed Director, Radiation Oncology of the Segal Most cancers Centre on the Jewish Common Hospital in August 2009.
Dr. Vuong is internationally acknowledged, notably for her experience within the remedy and analysis of rectal most cancers. Her present analysis focus is on excessive dose charge endorectal brachytherapy for sufferers with rectal most cancers. Her experience makes her a sought-after lecturer in each the educational and scientific communities. Her publications seem in internationally famend scientific journals.
Dr. Vuong conducts cutting-edge analysis within the space of colorectal most cancers. She has engaged in quite a few research all through her profession, as both the Principal Investigator or a co-participant. Her efforts have led to the event of latest radiation applied sciences and medical protocols for the remedy of gastrointestinal most cancers.
Santosh Kesari, MD, PhD, is a board-certified neurologist and neuro-oncologist and is presently Chair and Professor, Division of Translational Neurosciences and Neurotherapeutics, John Wayne Most cancers Institute. He’s additionally Director of Neuro-oncology at Pacific Neuroscience Institute, Windfall Saint John’s Well being Middle and Windfall Little Firm of Mary Medical Middle Torrance, and leads the Pacific Neuroscience Analysis Middle at Pacific Neuroscience Institute. Dr. Kesari is ranked among the many high 1% of neuro-oncologists and neurologists within the nation, based on Fort Connolly Medical Ltd and an internationally acknowledged scientist and clinician. He’s a winner of an Innovation Award by the San Diego Enterprise Journal. He’s on the advisory board of American Mind Tumor Affiliation, San Diego Mind Tumor Basis, Chris Elliott Fund, Nicolas Conor Institute, Voices Towards Mind Most cancers, and Philippine Mind Tumor Alliance. He has been the writer of over 250 scientific publications, critiques, or books. He’s the inventor on a number of patents and patent functions, and founder and advisor to many most cancers and neurosciences targeted biotech startups. As well as, he’s a member of the Los Angeles Biomedical Analysis Institute.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a world medical know-how chief offering modern most cancers detection and remedy options.
The Xoft® Axxent® Digital Brachytherapy (eBx®) System® is FDA-cleared, CE marked and licensed in a rising variety of international locations for the remedy of most cancers wherever within the physique. It makes use of a proprietary miniaturized x-ray supply to ship a exact, concentrated dose of radiation on to the tumor web site, whereas minimizing threat of injury to wholesome tissue in close by areas of the physique.
For extra info, go to www.icadmed.com and www.xoftinc.com.
Ahead-Trying Statements
Sure statements contained on this Information Launch represent “forward-looking statements” throughout the which means of the Non-public Securities Litigation Reform Act of 1995, together with statements concerning the future prospects for the Firm’s know-how platforms and merchandise. Such forward-looking statements contain quite a lot of recognized and unknown dangers, uncertainties and different components which can trigger the precise outcomes, efficiency or achievements of the Firm to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by such forward-looking statements. Such components embrace, however are usually not restricted, to the Firm’s potential to attain enterprise and strategic goals, the flexibility of IORT to supply flexibility, mobility or different benefits, to be extra useful for sufferers than conventional remedy or to be accepted by sufferers or clinicians, the influence of provide and manufacturing constraints or difficulties, product market acceptance, potential technological obsolescence of merchandise, elevated competitors, litigation and/or authorities regulation, adjustments in Medicare or different reimbursement insurance policies, dangers referring to our present and future debt obligations, aggressive components, the consequences of a decline within the economic system or markets served by the Firm; and different dangers detailed within the Firm’s filings with the Securities and Trade Fee. The phrases “consider,” “exhibit,” “intend,” “count on,” “estimate,” “will,” “proceed,” “anticipate,” “doubtless,” “search,” and comparable expressions establish forward-looking statements. Readers are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date the assertion was made. The Firm is below no obligation to supply any updates to any info contained on this launch. For extra disclosure relating to these and different dangers confronted by iCAD, please see the disclosure contained in our public filings with the Securities and Trade Fee, out there on the Traders part of our web site at http://www.icadmed.com and on the SEC’s web site at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Amy Prepare dinner, iCAD
acook@icadmed.com
Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568
jeremy@lifesciadvisors.com
